
News|Videos|July 11, 2024
De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis
Multiple sclerosis (MS) treatment specialists discuss the challenges associated with the early use of high-efficacy therapy (HET) in patients with mild to moderate MS and delve into the broader debate surrounding the consistent use of HET for managing mild to moderate MS cases.
Advertisement
Episodes in this series

Are there any challenges associated with early use of HET in patients with mild to moderate MS?
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia
2
Gene Therapy ETX101 Demonstrates Significant Effects on Seizure Reduction, Neurodevelopmental Outcomes in POLARIS Phase 1/2 Program
3
Overviewing Promising Phase 1/2 Data of Gene Therapy ETX101 in Dravet Syndrome: Joseph Sullivan, MD
4
Understanding the Mechanism and Rationale of Azetukalner to Treat Focal Epilepsy: Christopher Kenney, MD, FAAN
5



























